HomeCompareME vs XYLD

ME vs XYLD: Dividend Comparison 2026

ME yields 329.87% · XYLD yields 10.98%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ME wins by $2894.57M in total portfolio value
10 years
ME
ME
● Live price
329.87%
Share price
$0.61
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$2894.60M
Annual income
$1,813,268,323.14
Full ME calculator →
XYLD
Global X S&P 500 Covered Call ETF
● Live price
10.98%
Share price
$39.13
Annual div
$4.30
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$25.3K
Annual income
$3,219.02
Full XYLD calculator →

Portfolio growth — ME vs XYLD

📍 ME pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMEXYLD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ME + XYLD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ME pays
XYLD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ME
Annual income on $10K today (after 15% tax)
$28,038.92/yr
After 10yr DRIP, annual income (after tax)
$1,541,278,074.67/yr
XYLD
Annual income on $10K today (after 15% tax)
$933.63/yr
After 10yr DRIP, annual income (after tax)
$2,736.17/yr
At 15% tax rate, ME beats the other by $1,541,275,338.50/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ME + XYLD for your $10,000?

ME: 50%XYLD: 50%
100% XYLD50/50100% ME
Portfolio after 10yr
$1447.31M
Annual income
$906,635,771.08/yr
Blended yield
62.64%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ME right now

ME
Analyst Ratings
3
Buy
1
Hold
Consensus: Buy
Price Target
$3.71
+511.9% upside vs current
Range: $0.42 — $7.00
Altman Z
-26.6
Piotroski
3/9
XYLD
No analyst data
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ME buys
0
XYLD buys
0
No recent congressional trades found for ME or XYLD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMEXYLD
Forward yield329.87%10.98%
Annual dividend / share$2.00$4.30
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$2894.60M$25.3K
Annual income after 10y$1,813,268,323.14$3,219.02
Total dividends collected$2789.36M$19.6K
Payment frequencyquarterlymonthly
SectorStockETF

Year-by-year: ME vs XYLD ($10,000, DRIP)

YearME PortfolioME Income/yrXYLD PortfolioXYLD Income/yrGap
1← crossover$43,687$32,986.97$10,818$1,098.39+$32.9KME
2$181,427$134,682.32$11,738$1,222.51+$169.7KME
3$716,858$522,730.31$12,774$1,364.64+$704.1KME
4$2,697,334$1,930,296.36$13,944$1,527.86+$2.68MME
5$9,674,151$6,788,003.26$15,270$1,715.87+$9.66MME
6$33,104,222$22,752,880.42$16,775$1,933.09+$33.09MME
7$108,186,619$72,765,101.90$18,490$2,184.87+$108.17MME
8$338,003,420$222,243,737.65$20,450$2,477.63+$337.98MME
9$1,010,586,859$648,923,199.12$22,697$2,819.19+$1010.56MME
10$2,894,596,262$1,813,268,323.14$25,280$3,219.02+$2894.57MME

ME vs XYLD: Complete Analysis 2026

MEStock

23andMe Holding Co. operates as a consumer genetics testing company. It operates through two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications based on genetic testing of a saliva sample through its spit kit. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to improve patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing of intellectual property associated with identified drug targets related to drug candidates under clinical development. It has a collaboration agreement with GlaxoSmithKline Intellectual Property (No.3) Limited to leverage genetic insights to validate, develop, and commercialize drugs. The company was founded in 2006 and is headquartered in South San Francisco, California.

Full ME Calculator →

XYLDETF

The Global X S&P 500 Covered Call ETF (XYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe S&P 500 BuyWrite Index.

Full XYLD Calculator →
📬

Get this ME vs XYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ME vs SCHDME vs JEPIME vs OME vs KOME vs MAINME vs QYLDME vs JEPQME vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.